← Leaderboards
Stephen J Klaus
Fibrogen, Inc.
$980,635
Attributed
$980,635
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $497.2K · FY2006–07$500K$375K$250K$125K$0
'06
'07
Funding mix
By agency
NIH$980,635 · 3
By mechanism
R44$793,135 · 1
R43$187,500 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Erythropoiesis”
- Mitchell J Weiss · Children'S Hospital Of Philadelphia$19,279,721
- Mark T Groudine · Fred Hutchinson Cancer Research Center$17,066,504
- James J Bieker · Icahn School Of Medicine At Mount Sinai$15,613,141
- Leonard I Zon · Children'S Hospital Boston$15,527,566
- Emery H. Bresnick · University Of Wisconsin-Madison$13,397,093
- Merav Socolovsky · Whitehead Institute For Biomedical Res$13,034,205
Research focus
ErythropoiesisHydroxyureaSickle Cell AnemiaDrug Design /Synthesis /ProductionTranscription FactorAntineoplasticsAnimalsAnemiaBiologicalBioavailableBlood Disorder ChemotherapyBone MarrowCd34 GeneCell Cycle ProgressionAngiogenesis InhibitorsClinical Trials, Phase IiChronicBeta ThalassemiaCollagenCombinatorial ChemistryComplete Blood CountConceptConnective Tissue Growth FactorChemical Structure Function
Grant awards (4)
HbF Induction by Prolyl Hydroxylase Inhibitors in Non-human Primates$497,166
R44 · FY2007 · HL · contact PI
HbF Induction by Prolyl Hydroxylase Inhibitors$295,969
R44 · FY2006 · HL · contact PI
Induction of HbF by Prolyl Hydroxylase Inhibitors$87,500
R43 · FY2004 · HL
Development of CTGF antibodies that block angiogenesis$100,000
R43 · FY2003 · CA